1. LIAS Proud to Market ITL Pharma Products

2. ITL New Product Pipeline
Thyroid Hormone Replacement
Neurodegenerative Diseases
Parkinson’s Disease
Alzheimer’s Disease
Anti-inflammatories
Cancer Diagnostics
Cancer Therapies
Inflammation Diagnostics
Production Technologies
Formulation and Tableting

3. ITL #
Product Name
Indication
ThyroMaxTM
Primary Hypothyroidism
PolyPhetamineTM
ADHD
SuperGlutamineTM
Nutritional Gln Source
ParkinolTM
Parkinson’s Disease
Poly-DTM
AzololTM
Alzheimer’s Disease
PolythyroidTM
Poly-DA
Blu-TTM
Diagnostic for Ductal Carcinoma
CarcininTM
Antineoplastic
Blu-T
Diagnostic for Systemic Infection
Taric 1
Pim 2
SafeSerum®
Synthetic Serum Replacement
CardioSafe
Heart Reperfusion Protectant
Poly Glu
Formulation Excipient

4. Current Thyroid Products
ThyroMax® trademark-T3 drug candidate BCT303 completed Phase clinical trials
Pending patent for platform technology
T4 drug candidate BCT304, ready for IND submission
Reverse T3 drug candidate BCT307, ready for IND submission
Veterinary use, Evergreen Products
Additional 505(b)(2) applications already identified, including pain-relief, anti-abuse products
ThyroMax®
BCT303

5. ThyroMax® (BCT303)
The First Advance in Thyroid Replacement Therapy in More Than 50 Years
Lead T3 drug candidate to treat hypothyroidism
Through clinical trials
505(b)(2) drug
Utilizes platform technology for sustained effects and improved stability (pending patent)
ThyroMax®
BCT303

6. Hypothyroidism
A condition in which the thyroid gland does not make enough thyroid hormone.
Symptoms can be fatigue, depression and weight gain.
Most patients must take thyroid hormone replacement for the rest of their lives.
Thyroid Gland
ThyroMax®
BCT303

8. TARGET TISSUES

12. The Hypothyroid Market
10 million patients in U.S. taking 1 Tab/day = 3.65 Billion Tabs per year
Annual Sales $2/tab =
$ 7.3 Billion
10% mkt share = $730 Million/year
(COG = 6%)
80 million patients worldwide at 1 Tab/day=29 Billion tabs per $1.00/tab = $ 29 Billion
10% mkt share=$ 2.9 Billion in global sales annually
ThyroMax®
BCT303

13. We need a better solution.
Current Therapies
Therapy
Pro
Con
Synthroid® – T4
Long half-life in the blood
Not the active form of the drug (T3) Known lung cancer risk
Cytomel® – T3
The active form of the hormone
Can require multiple doses a day; can release active ingredient too quickly causing side effects; stability issues
Armour® Thyroid – T3/T4
Long clinical history
Dosing not dependable
Known Heart Arrhythmia Risk
We need a better solution.
ThyroMax®
BCT303

14. The Better Solution ThyroMax® All Hypothyroid patients can be managed
Single Day Dosing means better compliance
Better Manageability of Patients Symptoms
Stability issues eliminated
Reduction of Recalls

15. Time & Events ThyroMax® BCT303 April 2012 August 2012
FDA approved IND, began Phase-I clinical trials
August 2012
Completed Phase-I clinical trials
August 2014
Completed Phase-II/III clinical trials
1Q 2015
Submit NDA for market approval
1Q 2016
Market Launch
ThyroMax®
BCT303

16. What Makes This Business Opportunity Unique?
ThyroMax®
1st Single Dose-a-Day
Later Stage Development
Market Scale Manufacturing
Numerous off-label uses
Faster to Market
505 (b)(2)
Improved Product Stability
ThyroMax®
BCT303

17. Business Strategies Sale of Drug(s) and/or Technology
Co-Development Agreement
Out-Licensing
Commercialize Internally and/or IPO
ThyroMax®
BCT303